PAH and phenylketonuria: For instance, the pharmacological chaperone sapropterin (Kuvan) has already been approved as the first non-dietary treatment for patients suffering from phenylketonuria which results from a single amino acid alteration in phenylalanine hydroxylase (PHA) [66].